



# Announcement

**CHANGE**  
HEALTHCARE

April 20, 2020

## 2019-Novel Coronavirus (COVID-19)

Dear Valued Customer,

The following information applies to ClaimsXten and ClaimsXten Select customers who license the LCD\_PXDX\_FREQ\_MULTIDX, NCD\_PXDX\_FREQ\_MULTIDX and PXDX\_COVERAGE rules in the National and Local Coverage Determinations (NCD/LCD) KnowledgePack.

The purpose is to provide information about the Centers for Medicare & Medicaid Services (CMS) guidance with respect to certain NCD and LCD policies. Information about a soon to be issued Content Manager release designed to address the changes, is also included.

### **CMS Updates:**

CMS has issued the following guidance with respect to NCD and LCD policies.

### **CMS-1744-IFC: Medicare and Medicaid Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency**

During the PHE for the COVID-19 pandemic, it is possible that patients receiving services for respiratory related indications will be required to receive care in unexpected settings, including the home. This may be necessary as COVID-19 and other patients are shifted across healthcare settings to accommodate an increase in patient volume. Therefore, we are finalizing on an interim basis that we will not enforce the clinical indications for coverage across respiratory, home anticoagulation management and infusion pump NCDs and LCDs (including articles) allowing for maximum flexibility for practitioners to care for their patients. This enforcement discretion will only apply during the PHE for the COVID-19 pandemic. These policies include, but are not limited to:

- NCD 240.2 Home Oxygen.
- NCD 240.4 Continuous Positive Airway Pressure for Obstructive Sleep Apnea.
- LCD L33800 Respiratory Assist Devices (ventilators for home use).
- NCD 240.5 Intrapulmonary Percussive Ventilator.
- LCD L33797 Oxygen and Oxygen Equipment (for home use).
- NCD 190.11 Home Prothrombin Time/International Normalized Ratio (PT/INR)

Monitoring for Anticoagulation Management.

- NCD 280.14 Infusion Pumps.
- LCD L33794 External Infusion Pumps.

The LCD polices noted in the above referenced document are considered durable medical equipment LCD polices by CMS. Change Healthcare does not develop DME LCDs. Therefore, content updates specific to these LCD policies are not required.

With respect to the NCD polices noted in the above referenced document, only **NCD 190.11** for Home Prothrombin Time/International Normalized Ratio (PT/INR) will require a content update. This NCD policy is developed in the NCD\_PXDX\_FREQ\_MULTIDX and PXDX\_COVERAGE rules with an explicit outcome of covered and an implicit outcome of non-covered. Based on CMS-1744-IFC guidance, Change Healthcare will “temporarily” adjust the implicit outcome to silent as CMS will not enforce the clinical indications for coverage during the COVID-19 pandemic.

Additionally, Change Healthcare is currently assessing LCD and NCD policies developed in the LCD\_PXDX\_FREQ\_MULTIDX, NCD\_PXDX\_FREQ\_MULTIDX as well as PXDX\_COVERAGE rules that may address respiratory, home anticoagulation management and infusion pump coverage.

To date, the following LCDs have been identified, and the implicit non-covered outcome will be “temporarily” changed to silent for the following LCD in the jurisdictions identified.

**The LCD and NCD updates will be provided in the Content Manager release, targeted for April 28, 2020 at 6 p.m.**

**Editing:**

The table below will identify the LCDs impacted where Change Healthcare will apply an implicit outcome of “silent.”

<b>Policy Number</b>	<b>Companion Article/Articles</b>	<b>Internal Policy Numbers</b>	<b>Policy Title</b>	<b>Contractor Name</b>
L37348	A56974, A56161	242A201, 243B208	MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels	CGS
L37301	A57338, A56251	249A183, 250B175	MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory	Noridian

			Viral Panels	
L37315	A57340, A56255	244A291, 245B161	MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels	Noridian
L37713	A56851	270A172,271B186, 273A164, 274B173	MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels	Palmetto
L37764	A57579, A56169	218A166,219B168, 236A166, 237B164	MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels	WPS
L34149	A57224, A55984	For April 2020 LCD Release; 249A209; 250B195	Respiratory Care (Respiratory Therapy)	Noridian

**Contact Information**

For additional information or questions, log onto the Customer Hub <https://customerhub.changehealthcare.com/> and submit a case to Product Support. Product Support is also available by email at [cacd.support@changehealthcare.com](mailto:cacd.support@changehealthcare.com) or by phone at 1-888-474-4262.

Learn how Change Healthcare is providing technology and business support during the COVID-19 crisis: [www.changehealthcare.com/covid-19](http://www.changehealthcare.com/covid-19).

Thanks for your attention to this announcement,

**Change Healthcare**

**Disclaimer:** This notice contains CONFIDENTIAL information intended only for the use of Change Healthcare customers. If you are NOT the intended recipient of this notice or an agent or employee responsible for delivering it to the intended recipient, you are hereby notified that any unauthorized dissemination or copying of the notice or the information contained therein is strictly prohibited.

[Privacy Notice](#) [Terms of Use](#) [Code of Conduct](#) [Patents](#)

© 2020 Change Healthcare

To subscribe to receive future Change Healthcare CSAs, please [click here](#) and complete the online request form.

[Unsubscribe](#) from Change Healthcare Communications

You are receiving this email to [ariddle@changehealthcare.com](mailto:ariddle@changehealthcare.com) because you elected to receive Client Service Announcements from Change Healthcare.



3055 Lebanon Pike, Suite 1000  
Nashville, TN 37214